NCT00983463
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Enrolling by Invitation
Not specifiedAges 18–65ObservationalVanderbilt UniversityInvestigator-initiated
~45 participants
Updated 2025-12-18 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To identify and relatively quantify, using high performance liquid chromatography electrospray ionization mass spectrometry, select lipids and proteins present in human liver biopsies.
Measured over 2 years
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesTennessee1
Study leadership
- Charles R Flynn, PhD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
- Najji Abumrad, MD · STUDY_CHAIR · Vanderbilt University Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
18-65 year of age
Undergoing elective abdominal or bariatric surgery
May have normal or elevated ALT/AST levels
Exclusion
Presence of viral hepatitis
Significant alcohol use
Intercurrent infections
Use of any thiazolidinediones
What this trial measures
- To identify and relatively quantify, using high performance liquid chromatography electrospray ionization mass spectrometry, select lipids and proteins present in human liver biopsies.2 years
- To spatially profile, using matrix assisted laser desorption ionization time of flight mass spectrometry, select lipids and proteins present in human liver biopsies.2 years